Discovery of new non-steroidal FXR ligands via a virtual screening workflow based on Phase shape and induced fit docking.

No abstract is available for this paper.

• Publication year

  2012

• Venue

  Bioorganic & Medicinal Chemistry Letters

• Publication date

  2012-11-15

• Fields of study

  Medicine, Chemistry

• Identifiers
  DOI 10.1016/j.bmcl.2012.09.045PMID 23040732
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• 4-Methylenesterols from Theonella swinhoei sponge are natural pregnane-X-receptor agonists and farnesoid-X-receptor antagonists that modulate innate immunity.

  2012cited by this paper
• Discovery and optimization of 1,3,4-trisubstituted-pyrazolone derivatives as novel, potent, and nonsteroidal farnesoid X receptor (FXR) selective antagonists.

  2012cited by this paper
• Discovery That Theonellasterol a Marine Sponge Sterol Is a Highly Selective FXR Antagonist That Protects against Liver Injury in Cholestasis

  2012cited by this paper
• Discovery of sulfated sterols from marine invertebrates as a new class of marine natural antagonists of farnesoid-X-receptor.

  2011cited by this paper
• Farnesoid X receptor suppresses constitutive androstane receptor activity at the multidrug resistance protein-4 promoter.

  2011cited by this paper
• Discovery of a novel IKK-β inhibitor by ligand-based virtual screening techniques

  2011cited by this paper
• Rapid Shape-Based Ligand Alignment and Virtual Screening Method Based on Atom/Feature-Pair Similarities and Volume Overlap Scoring

  2011cited by this paper
• Optimization of a novel class of benzimidazole-based farnesoid X receptor (FXR) agonists to improve physicochemical and ADME properties.

  2011cited by this paper
• Targetting farnesoid-X-receptor: from medicinal chemistry to disease treatment.

  2010cited by this paper
• Current Trends in Ligand-Based Virtual Screening: Molecular Representations, Data Mining Methods, New Application Areas, and Performance Evaluation

  2010cited by this paper
• Novel approach for chemotype hopping based on annotated databases of chemically feasible fragments and a prospective case study: new melanin concentrating hormone antagonists.

  2009cited by this paper
• How To Optimize Shape-Based Virtual Screening: Choosing the Right Query and Including Chemical Information

  2009cited by this paper
• Discovery of XL335 (WAY-362450), a highly potent, selective, and orally active agonist of the farnesoid X receptor (FXR).

  2009cited by this paper
• Identification of a potent synthetic FXR agonist with an unexpected mode of binding and activation

  2008cited by this paper
• FXR: a promising target for the metabolic syndrome?

  2007cited by this paper
• Improved Methods for Side Chain and Loop Predictions via the Protein Local Optimization Program:  Variable Dielectric Model for Implicitly Improving the Treatment of Polarization Effects.

  2007cited by this paper
• Comparison of Topological, Shape, and Docking Methods in Virtual Screening

  2007cited by this paper
• FXR, a multipurpose nuclear receptor.

  2006cited by this paper
• Protein–ligand docking: Current status and future challenges

  2006cited by this paper
• Prediction of protein-ligand interactions. Docking and scoring: successes and gaps.

  2006cited by this paper
• A shape-based 3-D scaffold hopping method and its application to a bacterial protein-protein interaction.

  2005cited by this paper
• Natural Structural Variants of the Nuclear Receptor Farnesoid X Receptor Affect Transcriptional Activation*

  2003cited by this paper
• Successful shape-based virtual screening: the discovery of a potent inhibitor of the type I TGFbeta receptor kinase (TbetaRI).

  2003cited by this paper
• A chemical, genetic, and structural analysis of the nuclear bile acid receptor FXR.

  2003cited by this paper
• Successful shape-Based virtual screening: The discovery of a potent inhibitor of the type I TGFβ receptor kinase (TβRI)

  2003cited by this paper
• Generation of multiple farnesoid-X-receptor isoforms through the use of alternative promoters.

  2002cited by this paper
• 6alpha-ethyl-chenodeoxycholic acid (6-ECDCA), a potent and selective FXR agonist endowed with anticholestatic activity.

  2002cited by this paper
• Evaluation of a novel shape-based computational filter for lead evolution: application to thrombin inhibitors.

  2002cited by this paper
• Identification of a chemical tool for the orphan nuclear receptor FXR.

  2000cited by this paper
• Endogenous bile acids are ligands for the nuclear receptor FXR/BAR.

  1999cited by this paper
• Identification of a nuclear receptor for bile acids.

  1999cited by this paper
• Bile acids: natural ligands for an orphan nuclear receptor.

  1999cited by this paper

• Recent Advances for the Desaturation of Amides

  2025cites this paper
• Hepatic retinaldehyde deficiency is involved in diabetes deterioration by enhancing PCK1- and G6PC-mediated gluconeogenesis

  2023cites this paper
• Molecular dynamics articulated multilevel virtual screening protocol to discover novel dual PPAR α/γ agonists for anti-diabetic and metabolic applications

  2022influential citation
• Pharmacophore modeling and virtual screening studies for discovery of novel farnesoid X receptor (FXR) agonists

  2021cites this paper
• Novel natural scaffold as hURAT1 inhibitor identified by 3D-shape-based, docking-based virtual screening approach and biological evaluation.

  2021cites this paper
• Dolomiaea souliei ethyl acetate extract protected against α-naphthylisothiocyanate-induced acute intrahepatic cholestasis through regulation of farnesoid x receptor-mediated bile acid metabolism.

  2021cites this paper
• A Virtual Screening Platform Identifies Chloroethylagelastatin A as a Potential Ribosomal Inhibitor

  2020cites this paper
• Emerging targets and potential therapeutic agents in non-alcoholic fatty liver disease treatment.

  2020cites this paper
• Prediction of Farnesoid X Receptor Disruptors with Machine Learning Methods.

  2018cites this paper
• Advances in the Development of Shape Similarity Methods and Their Application in Drug Discovery

  2018cites this paper
• Pharmacophore Models for Toxicology Prediction

  2018cites this paper
• Opportunities and Challenges for Fatty Acid Mimetics in Drug Discovery.

  2017cites this paper
• Agonistes du récepteur x farnésoïde et leurs utilisations

  2016cites this paper
• Identification of potential dual agonists of FXR and TGR5 using e-pharmacophore based virtual screening.

  2015cites this paper
• Identifying farnesoid X receptor agonists by naïve Bayesian and recursive partitioning approaches

  2015cites this paper
• Discovery of New Non‐Steroidal Farnesoid X Receptor Modulators Through 3D Shape Similarity Search and Structure‐Based Virtual Screening

  2015cites this paper
• Discovery of 2-oxo-1,2-dihydrobenzo[cd]indole-6-sulfonamide derivatives as new RORγ inhibitors using virtual screening, synthesis and biological evaluation.

  2014cites this paper
• Medicinal chemistry and pharmacological effects of Farnesoid X Receptor (FXR) antagonists.

  2014cites this paper
• Recent advances in non-steroidal FXR antagonists development for therapeutic applications.

  2014cites this paper
• ROR nuclear receptors: structures, related diseases, and drug discovery

  2014cites this paper
• Hierarchical virtual screening approaches in small molecule drug discovery

  2014cites this paper
• Investigations on the Interactions of λPhage-Derived Peptides Against the SrtA Mechanism in Bacillus anthracis

  2014cites this paper
• Fragment-based Shape Signatures: a new tool for virtual screening and drug discovery

  2013cites this paper
• Bile Acid Receptors and Liver Cancer

  2013cites this paper